Bedaquiline Oral Tablet

DRUG2 trials

Sponsors

Wits Health Consortium (Pty) Ltd, Assistance Publique - Hôpitaux de Paris

Conditions

Antibiotic ResistanceExtensively Drug-Resistant TuberculosisMDR-TBMulti Drug Resistant TuberculosisMycobacterium TuberculosisPre-XDR-TBRifampicin Resistant TuberculosisTuberculosis

Phase 3

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

CompletedNCT04062201

Wits Health Consortium (Pty) LtdExtensively Drug-Resistant Tuberculosis, Multi Drug Resistant Tuberculosis, Pre-XDR-TB +2

Start: 2019-08-22End: 2024-04-15Updated: 2024-08-28

Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

Not yet recruitingNCT07486024

Assistance Publique - Hôpitaux de ParisAntibiotic Resistance, MDR-TB, Mycobacterium Tuberculosis +1

Start: 2026-04-01End: 2032-02-01Target: 55Updated: 2026-03-20